Research projects

Grant Awarded for Research into Identifying and Treating Chemotherapy-Resistant Neuroblastoma

Solving Kids’ Cancer UK with partners; Solving Kids’ Cancer in New York, Joining Against Cancer in Kids (J-A-C-K), ZOE4LIFE, Merryn Lacy Trust and the Oscar Knox Fund have awarded £500,000 to the Children’s Hospital of Philadelphia (CHOP) and collaborating institutions for research into identifying and treating neuroblastoma in newly diagnosed children that is resistant to current standard chemotherapy. Read more

Landmark Transatlantic Trial for Children with High-Risk Neuroblastoma Funded by Parent-Led Charities

In a landmark in paediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time. Read more

Grant awarded to open SIOPEN High-Risk Neuroblastoma Clinical Trial 2 across the UK in 2021

Grant Award - High-Risk Neuroblastoma Clinical Trial 2 Read more

Grant awarded to identify markers of poor survival in high-risk neuroblastoma

Solving Kids’ Cancer Europe, Solving Kids' Cancer in New York, Oscar Knox Fund and Merryn Lacy Trust have awarded a grant of $420,000 to co-investigators. Read more

Lorlatinib (PF-06463922) : Third-generation ALK inhibitor

This exciting new clinical trial sees 17 transatlantic centres in the UK, USA and Europe, recruiting patients simultaneously for an innovative new third-generation ALK-inhibitor agent lorlatinib (PF-06463922). Read more

National Neuroblastoma Genetics Reference Centre

The National Neuroblastoma Genetics Reference Centre aims to provide a comprehensive service genetic characterisation of all neuroblastoma tumours at diagnosis and a subset at relapse. Read more

Biomarker evaluation of neuroblastoma mRNAs in children enrolled in the BEACON trial

In this study, blood and bone marrow samples from 120 children treated in the BEACON-Neuroblastoma trial will be collected in order to analyse levels of neuroblastoma mRNAs Read more

MiNivAn : Phase I study of I-131 MIBG, nivolumab and ch14.18/CHO

MiNivAn aims to improve the cure rate of children with relapsed or refractory neuroblastoma by combining targeted radiotherapy (I-131 MIBG) with the antibodies anti-GD2 (ch14.18/CHO) and anti-PD1 (nivolumab). Read more

Neuroblastoma Senior Trials Coordinator

Solving Kids’ Cancer funds a dedicated Senior Trials Coordinator for Neuroblastoma within the Children’s Cancer Trials Team (CCTU) of the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham. Read more

PTPP – ITCC-P4 Collaboration

Bringing together American NCI PPTC and European ITCC-P4 paediatric preclinical research consortiums together for the first time ever via the Pediatric Cancer Working Group at the AACR Annual Meeting. Read more

BEACON Immuno (anti-GD2 amendment)

The BEACON study is a chemotherapy and antibody combination trial. Read more

International Neuroblastoma Research Initiative 2018

Solving Kids’ Cancer is leading an international competitive funding call commencing with a Request for Applications (RFA) Read more

International Research Initiative 2019

Solving Kids’ Cancer has issued a joint 2019 International Challenge Grant Call for GBP 500,000 awarded over three years Read more

Latest

Eden's Fundraising Pink Day

We are organising a PINK DAY fundraising event on Thursday 10th March which is also Eden’s 7th birthday and pink is her favourite colour. Therefore, it will simply involve wearing something pink and bringing a monetary donation to your school, college, business and/or workplace.

Some schools, colleges and businesses might consider additional fundraising opportunities on the day to raise further donations, such as games, cake sales, competitions and/or enterprising events.
Relapse Prevention Therapies: an in-depth look

In this special edition of our research blog, Research Director and Chair of Trustees Nick Bird looks at the landscape of maintenance therapies and their accessibility in the UK.
Aberlady Social Joggers

Fundraising for Flora's Fight from here running friends in Aberlady
Yorkshire 3 peaks for Beau

To get Beau to Sloan.

Beau's Campaign

Beau was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in December 2020. Her family are appealing for your help to raise £317,000 by May 2022.
Joseph Yeandle

We are devastated to share the news that beautiful Joseph has sadly passed away.
Flora's Campaign

In January 2021 Flora was diagnosed with Autism Spectrum Disorder, and just three months later her parents were given the devastating news she had high-risk neuroblastoma. Her family are appealing for your help to raise £312,000 by August 2022 for Flora to enrol on the Bivalent Vaccine clinical trial in New York that aims to stop her neuroblastoma from coming back.
Chloe’s Journey

Chloe was diagnosed with high-risk neuroblastoma at just 2 years old. Chloe is now 10 years old and in February 2020 her parents were given the devastating news that she had relapsed for the second time with her disease progressing in February 2021.
Maysaa's Campaign

Four-year-old Maysaa was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in March 2021. Her family are asking for your support to raise £106,000 by August 2022 for Maysaa to enrol on the DFMO study in Charlotte that aims to stop her neuroblastoma from coming back.
Peter's Campaign

11-year-old Peter was diagnosed with neuroblastoma in early 2019. Devastatingly he relapsed in August 2020 after being clear of disease for 6 months. His family are fundraising for further treatment either to get Peter back into remission or to try and keep the cancer away if his treatment goes to plan. This could cost hundreds of thousands of pounds.
Ollie Sweeney

Ollie's family shared the devastating news that their beautiful boy passed away on Sunday 18th July 2021.
Lily-Mae, Ireland’s Tiny Dancer, supports Solving Kids’ Cancer

Lily-Mae from Galway, Ireland will be celebrating her 12th birthday this April, but for her parents Judith and Leighton every day is a blessing.
Eden's Campaign

Six-year-old Eden was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in April 2021.
Henry's Urgent Appeal

Henry has high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis. His family are appealing for your help to raise £163,000 by January 2021.